Longitudinal cohort: patient demographics
| . | Allogeneic HSCT patients (N = 103) . |
|---|---|
| Age | |
| Median | 9.2 y |
| Range | 5 mo to 32 y |
| Sex | |
| Male | 68 |
| Female | 35 |
| Race | |
| White | 93 |
| African American | 8 |
| Asian | 2 |
| Diagnosis | |
| Immune deficiency | 32 |
| Bone marrow failure | 28 |
| Malignancy | 24 |
| Hemoglobinopathy | 14 |
| Metabolic | 5 |
| Stem cell source | |
| Bone marrow | 84 |
| Peripheral blood | 17 |
| Umbilical cord blood | 2 |
| Donor type | |
| Related | 37 |
| Unrelated | 66 |
| Match | |
| Fully matched | 77 |
| Mismatched | 26 |
| Conditioning regimen | |
| Myeloablative | 53 |
| Busulfan-based | 41 |
| Cyclophosphamide/total body irradiation | 8 |
| Cyclophosphamide/antithymocyte globulin | 4 |
| Reduced intensity | 50 |
| Campath/fludarabine/melphalan | 38 |
| Busulfan/Fludarabine | 6 |
| Other* | 6 |
| GVHD prophylaxis | |
| Calcineurin inhibitor-based | 90 |
| T-cell depletion | 12 |
| None | 1 |
| . | Allogeneic HSCT patients (N = 103) . |
|---|---|
| Age | |
| Median | 9.2 y |
| Range | 5 mo to 32 y |
| Sex | |
| Male | 68 |
| Female | 35 |
| Race | |
| White | 93 |
| African American | 8 |
| Asian | 2 |
| Diagnosis | |
| Immune deficiency | 32 |
| Bone marrow failure | 28 |
| Malignancy | 24 |
| Hemoglobinopathy | 14 |
| Metabolic | 5 |
| Stem cell source | |
| Bone marrow | 84 |
| Peripheral blood | 17 |
| Umbilical cord blood | 2 |
| Donor type | |
| Related | 37 |
| Unrelated | 66 |
| Match | |
| Fully matched | 77 |
| Mismatched | 26 |
| Conditioning regimen | |
| Myeloablative | 53 |
| Busulfan-based | 41 |
| Cyclophosphamide/total body irradiation | 8 |
| Cyclophosphamide/antithymocyte globulin | 4 |
| Reduced intensity | 50 |
| Campath/fludarabine/melphalan | 38 |
| Busulfan/Fludarabine | 6 |
| Other* | 6 |
| GVHD prophylaxis | |
| Calcineurin inhibitor-based | 90 |
| T-cell depletion | 12 |
| None | 1 |
Other: fludarabine/melphalan, 1; cyclophosphamide/antithymocyte globulin, 4; no conditioning, 1.